Method for selectively inhibiting the activity of ACAT1 in the treatment of alzheimer's disease
The present invention features methods for decreasing the size and density of amyloid plaques, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimer's disease by selectively inhibiting the activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2.
1. A method for treating Alzheimer's Disease comprising administering to a subject in need of treatment an effective amount of an siRNA or microRNA that inhibits the expression of Acyl-CoA:Cholesterol Acyltransferase 1 thereby treating the subject's Alzheimer's Disease, wherein the siRNA or microRNA comprises SEQ ID NO:37, 38, 39, 40, 43, or 44 and said siRNA or microRNA is administered via a liposome or nanoparticle.
2. The method of claim 1 , wherein the agent is selectively delivered to the brain of the subject.